Why Comparing Vaping to Smoking Always Misses the Point

The question 'is vaping safe?' is the wrong question. It's wrong because it implies a binary answer—safe or dangerous—when the reality is continuous. It's wrong because it omits the comparison that gives the answer meaning—safe compared to what? It's wrong because it ignores the population heterogeneity that determines whether vaping is beneficial or harmful—safe for whom? And it's wrong because it treats 'vaping' as a single thing when it's a category encompassing products with radically different risk profiles, used by different populations, in different ways. The vaping debate is trapped in bad questions, and bad questions produce bad answers. Here's how to ask better ones.

The most important missing comparator is cigarettes. The relevant question for the 1.3 billion smokers on Earth is not 'is vaping safe?' but 'is vaping safer than smoking?' The answer, based on the weight of toxicological, biomarker, and epidemiological evidence, is almost certainly yes—and the magnitude of the difference is large. E-cigarette aerosol contains far fewer toxicants at far lower concentrations than cigarette smoke, and the biomarkers of exposure in exclusive vapers are dramatically lower than in smokers. The long-term epidemiological evidence doesn't exist yet because vaping hasn't been widespread long enough, but the mechanistic evidence is strong and consistent: eliminating combustion eliminates the primary source of tobacco-related harm. For a smoker deciding whether to switch, the relevant comparison is not 'vaping vs. breathing air' but 'vaping vs. smoking.' The latter comparison yields a clear answer. The former comparison, while relevant for never-smokers, is irrelevant for the population that constitutes the vast majority of vapers: current and former smokers.

The population heterogeneity question is equally important and routinely ignored. 'Is vaping beneficial?' has no single answer because the effect of vaping on health depends on who's doing it. For a 45-year-old pack-a-day smoker with COPD who's failed to quit with NRT and varenicline, switching to vaping almost certainly reduces their disease risk and may improve their respiratory function. For a 15-year-old who's never smoked, initiating vaping introduces a nicotine addiction and an inhalation exposure that they wouldn't otherwise have, with uncertain long-term consequences for their developing brain and respiratory system. Both of these people are 'vapers,' but the health implications of their vaping are diametrically opposed. Policies that treat vaping as uniformly beneficial (ignore youth risk) or uniformly harmful (ignore adult cessation benefit) are optimizing for one population at the expense of the other. The better question is: 'for which populations, under what conditions, does vaping produce net health benefit or net health harm?'

The 'under what conditions' modifier is essential because vaping is not a single exposure. The risk profile of a JUUL pod used as directed by an adult ex-smoker is different from a high-wattage box mod used for 'cloud chasing' competitions, which is different from a black-market THC cartridge adulterated with vitamin E acetate, which is different from a disposable vape manufactured in an unregulated facility. The product, the use pattern, the source, and the regulatory context all matter enormously. A regulatory framework that treats all 'vaping' as a single category is as imprecise as a regulatory framework that treats all 'beverages' as a single category—collapsing water, coffee, beer, and bleach into one undifferentiated category and asking 'are beverages safe?' The question is nonsensical because the category is too broad. 'Is vaping safe?' is nonsensical for the same reason.

The time horizon question adds another dimension. 'Is vaping safe?' could mean 'does vaping cause acute harm within days or weeks?' (the answer, with the exception of the EVALI outbreak caused by an adulterant in illicit THC cartridges, is generally no). Or it could mean 'does vaping cause chronic harm over decades?' (the answer is unknown, because the exposure duration in the population is not yet sufficient). The distinction between acute and chronic risk matters enormously for policy, but it's collapsed in the binary 'safe/dangerous' framing. A product can be acutely safe and chronically uncertain—which is the most accurate characterization of vaping relative to smoking. Smoking is acutely dangerous (carbon monoxide poisoning, cardiovascular stress) AND chronically catastrophic (cancer, COPD, cardiovascular disease). Vaping is acutely safer AND chronically uncertain. Communicating this distinction honestly, without minimizing the uncertainty or exaggerating the certainty, is the central challenge of vaping risk communication.

The regulatory implications of the bad-question problem are substantial. When policymakers ask 'is vaping safe?' and hear 'no' (because nothing is perfectly safe), they enact policies that treat vaping and smoking as equivalent—equal taxation, equal advertising restrictions, equal access limits. When they ask 'is vaping safer than smoking?' and hear 'yes' (because the evidence supports this), they enact policies that incentivize the switch—differential taxation, honest risk communication, preserved access for adult smokers. The difference between these policy frameworks, applied across populations and sustained over decades, is measured in millions of preventable deaths. The question isn't academic. It's the most consequential policy question in tobacco control, and it's being answered poorly because it's being asked poorly.

The way out of the bad-question trap is to replace binary questions with continuous ones. Not 'is vaping safe or dangerous?' but 'what is the risk of vaping compared to smoking, for which populations, under what conditions, over what time horizon?' This question admits of nuanced answers because it demands them. It doesn't fit on a bumper sticker, and it doesn't produce the clean, mobilizing messages that advocacy organizations prefer. But it has the singular advantage of being answerable with the evidence we have, and of directing research toward the evidence we still need. The vaping debate has been raging for over a decade, and in many respects, it's no closer to resolution than when it started. That's not because the evidence hasn't advanced. It's because the questions haven't. Better evidence requires better questions. And the first and most important question—compared to what?—is the one that's most consistently left unasked.